Organism Function – Page 3

EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies

6 months ago talkbio0Tagged AMD, anti-VEGF therapy, Clinical Trials, DURAVYU, EyePoint Pharmaceuticals, Glycogen storage disease type II, Movement, Prices, vorolanib

DURAVYU, vorolanib, wet AMD, anti-VEGF therapy, EyePoint Pharmaceuticals, clinical trial results, stock price movement

Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026

6 months ago talkbio0Tagged 2025, CagriSema, Drug Industry, Growth, Nordisk, Obesity, regulatory approval, Sales - occupational activity, Wegovy

Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval

FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment

6 months ago talkbio0Tagged Approved, Continuous Delivery, dimethylethylsilylimidazole, Macular edema due to diabetes mellitus, Ophthalmological implant, ranibizumab, Roche (company), Susvimo, United States Food and Drug Administration, Vision

Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement

Novo Nordisk Projects Slower Growth for 2025 Despite Wegovy’s Strong Q4 Performance

6 months ago talkbio0Tagged Drug Industry, Growth, Nordisk, Obesity, Sales - occupational activity, Wegovy

Novo Nordisk, Wegovy, obesity drugs, sales growth, 2025 outlook, pharmaceutical industry

AstraZeneca Cancels £450 Million UK Vaccine Plant Expansion Amid Government Funding Reduction

6 months ago talkbio0Tagged Administration occupational activities, AstraZeneca, Drug Industry, Economic Growth, Government, Investments, Labor (Childbirth), Manufacturing, UK, Vaccines

AstraZeneca, vaccine manufacturing, UK investment, government funding, Labour administration, economic growth, pharmaceutical industry

Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

6 months ago talkbio0Tagged Antibodies, Beyfortus, blockbuster sales, Growth, Infant, Market, Protection, Respiratory syncytial virus, sanofi, U.S.

Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus

Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models

6 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Architecture, House mice, melanin-concentrating hormone, orexins, Sleep, Sleep disturbances, Study models, suvorexant

Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models

Trump’s Second Term: Mifepristone Battle Looms as Early Test of Abortion Stance

6 months ago talkbio0Tagged court, mifepristone, Reproduction, Supreme, Transplant Registry Unified Management Program, United States Food and Drug Administration, Unspecified Abortion

Mifepristone, abortion, Trump, second term, reproductive rights, FDA, Supreme Court

Alzheimer’s Market Set for Eightfold Boom: Lilly, Eisai, and Biogen Lead the Charge

6 months ago talkbio0Tagged Alzheimer 's disease, Biogen, Donanemab, Eisai, Eli, Eli Lilly, Growth, Kisunla, Leqembi, Market

Alzheimer’s disease market, Eli Lilly, Eisai, Biogen, Market growth, Donanemab (Kisunla), Leqembi

Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema

7 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Biotechnology, Clinical Development, Cornea, Corneal endothelial dysfunction, Edema, Phase 2 Clinical Trials, Vision

Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development